Spelman, T. Et Al. 2024. Comparative effectiveness and cost-effectiveness of natalizumab and fingolimod in rapidly evolving severe relapsing-remitting multiple sclerosis in the United Kingdom. Journal of medical economics , vol.27, no.1 , 109-125.

Spelman, T., Herring, W., Acosta, C., Hyde, R., Jokubaitis, V., Pucci, E., ... Lugaresi, A.(2024). Comparative effectiveness and cost-effectiveness of natalizumab and fingolimod in rapidly evolving severe relapsing-remitting multiple sclerosis in the United Kingdom. Journal of medical economics , vol.27, no.1, 109-125.

Spelman, T. Et Al. "Comparative effectiveness and cost-effectiveness of natalizumab and fingolimod in rapidly evolving severe relapsing-remitting multiple sclerosis in the United Kingdom," Journal of medical economics , vol.27, no.1, 109-125, 2024

Spelman, T. Et Al. "Comparative effectiveness and cost-effectiveness of natalizumab and fingolimod in rapidly evolving severe relapsing-remitting multiple sclerosis in the United Kingdom." Journal of medical economics , vol.27, no.1, pp.109-125, 2024

Spelman, T. Et Al. (2024) . "Comparative effectiveness and cost-effectiveness of natalizumab and fingolimod in rapidly evolving severe relapsing-remitting multiple sclerosis in the United Kingdom." Journal of medical economics , vol.27, no.1, pp.109-125.

@article{article, author={T. Spelman Et Al. }, title={Comparative effectiveness and cost-effectiveness of natalizumab and fingolimod in rapidly evolving severe relapsing-remitting multiple sclerosis in the United Kingdom}, journal={Journal of medical economics}, year=2024, pages={109-125} }